Home Dialysis Plus (HD Plus), headquartered in Sunnyvale, California, is a private company focused on the development of a novel home kidney dialysis system. The company’s product, called Tablo, offers a dramatically improved treatment modality for patients suffering from end-stage renal disease, a life-threatening chronic condition affecting more than 600,000 people annually in the US. By allowing these patients to dialyze from home in a user-friendly and cost-effective manner, Tablo offers the potential to improve clinical outcomes and quality of life. HD Plus has largely completed product development, has successfully completed a series of preclinical and first-in-man trials, and expects to submit for its initial 510(k) clearance in 2014.
Warburg Pincus led a Series A investment in HD Plus in 2010 and has continued to provide additional growth capital and ongoing strategic support.
Back to Previous Page